- Conditions
- Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- Interventions
- ExPEC9V, Placebo, HD quadrivalent influenza vaccine
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 959 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- Interventions
- ExPEC9V, Placebo
- Biological · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 17,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 142
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more
- Conditions
- Extraintestinal Pathogenic Escherichia Coli Prevention
- Interventions
- ExPEC10V, ExPEC4V, Prevnar 13, Placebo
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 836 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Melbourne, Florida • Miami, Florida + 9 more